P31751

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession AKT2_HUMAN; P31751;
Entrez ID 208
GenBank Protein ID NM_001330511.1; NM_001626.5; XM_011526614.1; XM_011526615.1; XM_011526616.1; XM_011526618.1; XM_011526619.1; XM_011526620.1; XM_017026470.1;
GenBank Nucleotide ID NP_001317440.1; NP_001617.1; XP_011524916.1; XP_011524917.1; XP_011524918.1; XP_011524920.1; XP_011524921.1; XP_011524922.1; XP_016881959.1;
Protein Name RAC-beta serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase Akt-2) (Protein kinase B beta) (PKB beta) (RAC-PK-beta)
Gene Name AKT2
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionAKT2 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the (view all)
Sequence
(Fasta)
MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC 60
QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWM RAIQMVANSL KQRAPGEDPM 120
DYKCGSPSDS STTEEMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM 180
KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGELFFH 240
LSRERVFTEE RARFYGAEIV SALEYLHSRD VVYRDIKLEN LMLDKDGHIK ITDFGLCKEG 300
ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE 360
LILMEEIRFP RTLSPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK 420
KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG LLELDQRTHF PQFSYSASIR 480
E 482

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationRecessive Parkinson diseaseA23261939
[Reference]: The?phosphorylation?of Akt and ERK following exposure to H(2)O(2) or MPP(+) was also inhibited in PINK1 P209A mutant cells compared with empty vector-transfected cells.
2PhosphorylationBreast cancer/tumor/carcinomaD24425749
[Reference]: the activation of AMPK; (2) the inhibition of PI3K, AKT, and ERK; (3) an increase in markers of?proteinsynthesis inhibition at the level of translation elongation; and (4) an increase in autophagy markers
3PhosphorylationCancer cachexia/Cachexia/Cachectic tumorP23268279
[Reference]: PIF can induce cancer cachexia possibly by activating Akt?phosphorylation?and inducing downstream proteolysis.
4PhosphorylationRhabdomyosarcomaP14633723
[Reference]: We found that although HGF, similar to SDF-1, did not affect the proliferation of RMS cells, it induced in several of them: (a) locomotion; (b) stress fiber formation; (c) chemotaxis; (d) adhesion to human umbilical vein endothelial cells; (e) trans-Matrigel invasion and matrix metalloproteinase secretion; and (f) phosphorylation of mitogen-activated protein kinase p42/44 and AKT.
5Serine PhosphorylationOvarian cancer/carcinomaUS47410822383; 14597629
[Reference]: Here, we show that 1) TGF-beta1 induced a rapid increase of the PI3K activity that was accompanied by increased expression (5-fold) of the uPA mRNA; 2) pharmacological inhibition of PI3K or AS-PI3K ODN transfection inhibited TGF-beta1-stimulated Akt phosphorylation; 3) both PI3K pharmacological inhibitors and forced expression of AS-PI3K ODN reduced TGF-beta1-stimulated uPA mRNA and protein expression by approximately 70% compared with controls; 4) concentrations of PI3K inhibitors, sufficient to inhibit uPA up-regulation, inhibited TGF-beta1-dependent HRA cell invasion; 5) the AS-PI3K ODN cells had a decreased ability to invade the extracellular matrix layer as compared with controls; and 6) when the AS-PI3K ODN cells were injected intraperitoneally into nude mice, the mice developed smaller intraperitoneal tumors and showed longer survival.;

※ Disease Cross-ref Annotation

DatabaseAnnotation
Cancer Gene Census
ovarian, pancreatic
CTD (Curated)
(count: 5)
MESH:D001943 ; Breast Neoplasms
MESH:D003924 ; Diabetes Mellitus, Type 2
OMIM:240900 ; HYPOINSULINEMIC HYPOGLYCEMIA WITH HEMIHYPERTROPHY
MESH:D052496 ; Lipodystrophy, Familial Partial
MESH:C538339 ; Nasopharyngeal carcinoma
DisGeNet (Curated)
(count: 28)
(view all)
C0000889; Acanthosis Nigricans
C0005586; Bipolar Disorder
C0011860; Diabetes Mellitus, Non-Insulin-Dependent
C0014544; Epilepsy
C0018418; Gynecomastia
C0019209; Hepatomegaly
HGMD
(count: 1)
CM041234; Severe insulin resistance and diabetes mellitus; Missense/nonsense
GWASdb
(count: 3)
rs969531; Fibrinogen; cardiovascular system disease
rs969531; Progressive supranuclear palsy; progressive supranuclear palsy
rs7250897; Fibrinogen; cardiovascular system disease

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 29)
(view all)
122       PGEDPMDYKCGSPSD     dbPAF
126       PMDYKCGSPSDSSTT     dbPAF
128       DYKCGSPSDSSTTEE     dbPAF
130       KCGSPSDSSTTEEME     dbPAF
131       CGSPSDSSTTEEMEV     dbPAF
133       SPSDSSTTEEMEVAV     dbPAF
Acetylation
(count: 1)
386       SLLAGLLKKDPKQRL     PLMD
Ubiquitination
(count: 12)
(view all)
111       QMVANSLKQRAPGED     PLMD
14        IKEGWLHKRGEYIKT     PLMD
142       EMEVAVSKARAKVTM     PLMD
146       AVSKARAKVTMNDFD     PLMD
156       MNDFDYLKLLGKGTF     PLMD
160       DYLKLLGKGTFGKVI     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource